Regeneron Reports Five-year Results From Final Pre-specified Overall Survival Analysis Of Phase 3 EMPOWER-Lung 1 Trial; Says Results Showcase Durable Survival Benefit And Impressive Efficacy
Portfolio Pulse from Benzinga Newsdesk
Regeneron has announced the five-year results from the Phase 3 EMPOWER-Lung 1 trial, highlighting the durable survival benefits and impressive efficacy of Libtayo monotherapy. The treatment nearly doubled median overall survival and significantly reduced the risks of death and disease progression compared to chemotherapy.
September 09, 2024 | 9:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Regeneron's Libtayo monotherapy demonstrated significant efficacy in the Phase 3 EMPOWER-Lung 1 trial, nearly doubling median overall survival and reducing death and disease progression risks compared to chemotherapy.
The positive results from the EMPOWER-Lung 1 trial are likely to boost investor confidence in Regeneron's Libtayo, potentially leading to increased adoption and sales. This could positively impact Regeneron's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100